Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Human Umbilical Cord Stroma MSC in Myocardial Infarction (HUC-HEART)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02323477
Recruitment Status : Terminated (Due to budget limitations as allocated for a given period.)
First Posted : December 23, 2014
Last Update Posted : July 10, 2020
Sponsor:
Collaborators:
Hacettepe University
Turkiye Yuksek Ihtisas Education and Research Hospital
ATIGEN-CELL
Dr. Sami Ulus Children's Hospital
Ankara Yildirim Beyazıt University
Information provided by (Responsible Party):
Alp Can, Ankara University

Brief Summary:
The purpose of this phase 1/2 clinical trial is to evaluate the efficacy and safety of allogeneic human umbilical cordstroma derived multipotent stem cells (hUCS-MSCs) in myocardial infarction (MI). All subjects will be taken into the bypass coronary surgery prior to the cell administration. This 2-year study comprise three independent groups, where the first group (n=20) will take no cells, second group will take autologous BM-MNCs (n=20), and third group (n=39) will be receiving allogeneic hUCS-MSCs. In all transplantations cells will be administered to the approximately 10 peri-infarct areas at one time. The infarct zone will be determined by the MR, SPECT and PET imaging. Only male subjects between 30-80 years of age. The efficiency of the therapy will be evaluated according to the parameters measured by MR, SPECT, and Echocardiography. All subject were taken into those measurements prior and 6, 12, 18 and 24 months after the operation.

Condition or disease Intervention/treatment Phase
Chronic Ischemic Cardiomyopathy Coronary Artery Bypass Surgery Biological: stem cell transplantation Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 46 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: The Efficacy and Safety Assessment of Human Umbilical Cord Stroma-derived Multipotent Stromal Cells in Myocardial Infarction; a Phase 1/2 Clinical Trial (HUC-HEART Study)
Actual Study Start Date : February 2, 2015
Actual Primary Completion Date : September 30, 2018
Actual Study Completion Date : December 30, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Attack

Arm Intervention/treatment
Experimental: Allogeneic umbilical cord MSC group
Allogeneic human umbilical cord MSCs will be transplanted to 39 male patients (age 30-80) intramyocardially during CABG in chronic ischemic cardiomyopathy (EF<%45)
Biological: stem cell transplantation
Human allogeneic umbilical cord MSC or autologous BM-MNC transplantation

Active Comparator: Autologous bone marrow-derived MNC group
Autologous bone marrow-derived MNCs will be transplanted to 20 male patients (age 30-80) intramyocardially during CABG in chronic ischemic cardiomyopathy (EF<%45)
Biological: stem cell transplantation
Human allogeneic umbilical cord MSC or autologous BM-MNC transplantation

No Intervention: Control group
20 male patients (age 30-80) undergoing CABG in chronic ischemic cardiomyopathy (EF<%45) whom will not received any further transplantation



Primary Outcome Measures :
  1. ventricular remodeling [ Time Frame: within one year after cell transplantation ]
    Outcome measures will be determined by cardiac MR, SPECT and PET monitoring to assess the left ventricular ejection fraction (%), left ventricle end-diastolic and end-systolic volumes (mL/m2), left ventricle mass (g/m2), infarct size (%), and the thickness of the dysfunctional wall (mm).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ischemic hearth disease who will experience CABG
  • %25<EF<%45
  • NYHA class II-IV patients
  • hemodynamically stable

Exclusion Criteria:

  • Patient's in approval
  • Acute cardiac decompensation
  • Acute myocardial infarction
  • Congenital heart disease
  • Additional surgical heart disease other than coronary artery disease
  • Malign arrhythmia
  • All malignancies
  • HbA1c level >%10 (86 mmol/mol) type II diabetes mellitus
  • Severe liver dysfunction
  • Severe COPD
  • Coagulopathy
  • Immunosuppressive treatment
  • Acute hepatitis, hepatitis B, C and HIV infection
  • Chronic liver and renal failure
  • Collagen tissue disease
  • Stroke
  • TB
  • Hematological diseases
  • Socially and mentally disabilities

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02323477


Locations
Layout table for location information
Turkey
Alp Can
Ankara, Turkey, 06100
Sponsors and Collaborators
Ankara University
Hacettepe University
Turkiye Yuksek Ihtisas Education and Research Hospital
ATIGEN-CELL
Dr. Sami Ulus Children's Hospital
Ankara Yildirim Beyazıt University
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Alp Can, Prof. Dr., Ankara University
ClinicalTrials.gov Identifier: NCT02323477    
Other Study ID Numbers: 741.STZ.2014
First Posted: December 23, 2014    Key Record Dates
Last Update Posted: July 10, 2020
Last Verified: July 2020
Keywords provided by Alp Can, Ankara University:
cellular therapy
chronic ischemic heart disease
phase 1/2 clinical study
human umbilical cord multipotent stem cell
human umbilical cord mesenchymal stem cell
ischemic heart disease
bone marrow mononuclear cell
allogeneic stem cell transplantation
Additional relevant MeSH terms:
Layout table for MeSH terms
Myocardial Infarction
Cardiomyopathies
Infarction
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases